Company news
Entera Bio Ltd. news in 2020
Entera Bio Ltd.'s news releases, calls and decks from 2020, newest first.
Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis
December 9, 2020
Entera Bio Appoints Spiros Jamas as Chief Executive Officer
November 29, 2020
Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update
November 18, 2020
Entera Bio to Report Third Quarter 2020 Business and Financial Results on November 19, 2020
November 12, 2020
Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis
November 8, 2020
Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results
August 19, 2020
Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
August 16, 2020
Entera Bio Announces Management Changes
August 9, 2020
Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results
July 21, 2020
Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis
July 6, 2020
Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results
May 20, 2020
Entera Bio to Report Interim Data From EB613 Phase 2 Trial and First Quarter 2020 Business and Financial Results on May 21, 2020
May 6, 2020
Entera Bio Ltd announces financial and operating results for the fourth quarter and Year Ended December 31, 2019
March 25, 2020
Entera Bio to report 2019 business and financial results on March 26, 2020
March 15, 2020